Conduct↦Monitoring↦Routine Monitoring Visit↦Report
What is it? Why is it important?
Performed activities during a Routine Monitoring Visit (RMV), including recorded findings, are documented in a monitoring report.
The report summarises the assessment of performed monitoring activities, such as:
- The compliance with participant Informed Consent (IC) procedures (i.e. dated and signed by both study participants and Site-INV)
- The exclusive use of Ethics Committee (EC) and, if applicable, RA (e.g. Swissmedic) approved study documents (e.g. study protocol, IC / PIS forms, CRF)
- Database (CDMS) entries correspond with information recorded in the Source Data (SD) of the study
- Compliance with required safety reporting procedures (e.g. complete and timely reporting)
- The correct handling of the therapeutic product under investigation (IMP / IMD) handling (e.g. storage conditions, accountability-Log, access protected)
- The correct handling and documentation of biological material
- The documentation of protocol or ICH-GCP non-compliance
- The ongoing timely handling and correction of previously recorded findings requiring corrective measures (e.g. CAPAs)
What do I need to do?
If you are the study monitor:
- Write the RMV report and include the monitoring scope as defined in the Monitoring Plan (MP)
- Include any current and ongoing unresolved issues / findings, and provide guidelines on how to resolve them (e.g. CAPAs)
- Forward the report to the SP-INV for review and approval. Include in the report and changes made by the SP-INV
- Make sure both you, as a monitor, and the SP-INV date and sign the final report
- File the report in the TMF
The site does not receive a copy of the RMV report. However, the Site-INV receives a follow-up letter / e-mail summarising the visit, which is filed in the ISF.
In the event of remaining open issues / findings, check back with the study site at some later date. Provide any additional support needed to resolve them. Document and explain the resolution of previously open issues / findings in a subsequent interim report.
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R3) – see in particular guidelines
- Glossary: definition monitoring
- Glossary: definition monitoring report
- Glossary: definition monitoring plan
- 3.10.1.3 Risk control
- 3.11.4 Monitoring
- 3.11.4.5 Monitoring activities
- 3.11.4.5.1 Communication with parties conducting the trial
- 3.11.4.6 Monitoring report
- Essential records table: Site monitoring report
ICH E8 – see in particular guideline
- 6.3 Study reporting
- 6.2.1 Safety monitoring
ISO 14155 Medical Device – see in particular section (access liable to costs)
- 9.2.4.7 Monitoring reports